China-based biotechnology company HitGen has entered a drug discovery research collaboration with German firm Boehringer Ingelheim to discover new small molecule leads.

HitGen has set up a new platform for drug discovery research centred around Deoxyribonucleic acid (DNA)-encoded chemical libraries (DELs), which comprise more than 90 billion new and varied drug-like small molecule and macrocycle compounds.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

HitGen Board chairman and CEO Dr Jin Li said: “We are delighted to enter this collaboration with Boehringer Ingelheim, a major research based pharmaceutical company providing worldwide benefits to patients.

“This collaboration further emphasises the role of HitGen in the rapidly developing field of DNA-encoded chemistry.

“We will work closely with Boehringer Ingelheim scientists to generate new lead compounds for their research programmes to address unmet medical needs.”

“This collaboration further emphasises the role of HitGen in the rapidly developing field of DNA-encoded chemistry.”

As part of the collaboration, the company will apply its advanced technology platform, based on DNA-encoded library design, synthesis and screening, to identify new leads for targets of interest to Boehringer Ingelheim.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Boehringer Ingelheim Research Germany senior vice-president Eric Haaksma said: “We are very excited about the opportunity to complement our in-house expertise in the field of small molecule therapeutics research with HitGen’s DNA encoded library platform.

“We believe that HitGen’s screening capabilities of huge chemical spaces in combination with Boehringer Ingelheim’s skills in optimising HitGen’s hits to novel drugs could speed-up the provision of innovative medicines.”

Under the deal, HitGen will be eligible for receiving upfront and milestone payments from Boehringer.

Specific financial details of the collaboration have not yet been disclosed.